Speak directly to the analyst to clarify any post sales queries you may have.
The active pharmaceutical ingredients market is forecasted to grow by USD 86.47 billion during 2023-2028, accelerating at a CAGR of 6.73% during the forecast period. The report on the active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by evolving api manufacturing scenario in developing scenario, increasing number of type II drug master files (DMF), and growing need to focus on core competencies.
The active pharmaceutical ingredients market is segmented as below:
By Manufacturing Type
- Captive APIs
- Contract APIs
By Type
- Innovative APIs
- Generic APIs
By Geographical Landscape
- Asia
- North America
- Europe
- Rest of World (ROW)
This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredients market growth during the next few years. Also, increasing patent exercises and increasing geriatric population will lead to sizable demand in the market.
The report on the active pharmaceutical ingredients market covers the following areas:
- Active pharmaceutical ingredients market sizing
- Active pharmaceutical ingredients market forecast
- Active pharmaceutical ingredients market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
The analyst recognizes the following companies as the key players in the global active pharmaceutical ingredients market: AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is paradigm shift in API manufacturing.'
According to the report, one of the major drivers for this market is the evolving API manufacturing scenario in developing scenario.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Cadila Pharmaceuticals Ltd.
- Cambrex Corp.
- Cipla Ltd.
- Dr Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Indena S.p.A.
- INTERNATIONAL CHEMICAL INVESTORS S.E.
- Koninklijke DSM NV
- Lupin Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Viatris Inc.
